Boston Pharma mulls IPO amid MASH momentum

The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And another late-stage startup is gaining traction. Boston Pharmaceuticals, advancing a once-monthly liver disease drug ...

Related Posts

Bayer eyes capital raise as it grapples with Monsanto c...

Mar 7, 2025  0

Drugmakers tell court to keep hospitals out of their 34...

Feb 20, 2025  0

CDC investigating hospitalizations after chikungunya va...

Feb 27, 2025  0

Comments

Name

Email

Comment

Post Comment